MedTrace Logo

Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4

NCT01726309 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 161

Last updated 2025-07-08

No results posted yet for this study

Summary

Primary Objective:

Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.

Secondary Objectives:

Correlation of SNP profile with indicators of tumour response parameters, such as radiological response, duration of response, time to progression (TTP), overall survival (OS) time, incidence of non-dermatological adverse events.

Conditions

Sponsors & Collaborators

  • Cancer Trials Ireland

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2021-05-11
Completion
2021-05-11

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01726309 on ClinicalTrials.gov